Nuclear Medicine Set for Continued Growth Driven by Demand for Precision Diagnostics
Posted on 03 Feb 2026
Clinical imaging services face rising demand for precise molecular diagnostics and targeted radiopharmaceutical therapy as cancer and chronic disease rates climb. A new market analysis projects rapid expansion of nuclear medicine, indicating how modalities, end users, and regions are likely to drive growth through 2030.
The analysis by MarketsandMarkets forecasts the nuclear medicine market to grow from USD 10.41 billion in 2025 to USD 21.01 billion by 2030, representing a 15.1% compound annual growth rate. Diagnostic nuclear medicine held a larger share than therapeutic applications in 2024, reflecting widespread use of positron emission tomography (PET) and single-photon emission computed tomography (SPECT) for noninvasive detection and longitudinal monitoring. Continued radiotracer innovation and imaging system advancements are cited as contributors to diagnostic utility.
Adoption is being propelled by the need for accurate disease characterization in oncology, cardiology, and neurology. Expanding theranostic approaches and the introduction of novel radioisotopes are moving the field toward more personalized, targeted care. Improvements such as digital PET, AI-based image analysis, and automated dose dispensing are described as enhancing diagnostic precision and operational efficiency.
Hospitals are projected to be the fastest-growing end user segment. Investment in advanced imaging suites, development of in-house nuclear medicine capabilities, and expansion of hospital radiopharmacies are highlighted as drivers. Integrated diagnostic services that streamline workflow and support multidisciplinary decision-making are expected to reinforce this trajectory.
North America is projected to lead regional growth. The region’s established radiopharmaceutical manufacturing and distribution networks, strong healthcare infrastructure, wide access to nuclear medicine services, and an active regulatory environment supporting new tracers and indications are identified as key factors.
Related Links
MarketsandMarkets
